Azacitidine: Transforming Treatment in Myelodysplastic Syndromes

Created using ChatSlide

Explore the safety and efficacy of Azacitidine, the groundbreaking FDA-approved drug enhancing survival rates in myelodysplastic syndromes (MDS). This presentation examines MDS as a clonal myeloid disorder characterized by epigenetic changes, and details Azacitidine's mechanism, integrating into RNA/DNA and inhibiting DNMT, thereby reactivating suppressed genes. Clinical studies like CALGB 9221 and AZA-001 underscore its effectiveness, showcasing significant response rates and improved...